Cite
MLA Citation
R Alten et al.. “AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation.” Annals of the rheumatic diseases, vol. 76, n.d., pp. 1193–1194. http://access.bl.uk/ark:/81055/vdc_100135161961.0x000062